0001011034-17-000050.txt : 20170601 0001011034-17-000050.hdr.sgml : 20170601 20170601160831 ACCESSION NUMBER: 0001011034-17-000050 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170601 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20170601 DATE AS OF CHANGE: 20170601 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VITRO DIAGNOSTICS INC CENTRAL INDEX KEY: 0000793171 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 841012042 STATE OF INCORPORATION: NV FISCAL YEAR END: 1031 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17378 FILM NUMBER: 17884817 BUSINESS ADDRESS: STREET 1: 4621 TECHNOLOGY DRIVE CITY: GOLDEN STATE: CO ZIP: 80403 BUSINESS PHONE: (720) 859-4120 MAIL ADDRESS: STREET 1: 4621 TECHNOLOGY DRIVE CITY: GOLDEN STATE: CO ZIP: 80403 FORMER COMPANY: FORMER CONFORMED NAME: LABTEK INC DATE OF NAME CHANGE: 19870217 FORMER COMPANY: FORMER CONFORMED NAME: IMPERIAL MANAGEMENT INC DATE OF NAME CHANGE: 19870201 8-K 1 vitro_8k.htm VITRO DIAGNOSTICS, INC. UNITED STATES

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of Report (Date of earliest event reported):       June 1, 2017




VITRO DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in its Charter)



       Nevada       

       0-17378       

    84-1012042    

(State or other jurisdiction
of incorporation)

Commission File
Number

(I.R.S. Employer Identification number)



4621 Technology Drive, Golden CO  80403
(Address of principal executive offices)                    (Zip Code)


Registrant's telephone number, including area code:   (303) 999-2130


______________________________________________________

(Former name or former address, if changed since last report)



___

Written communications pursuant to Rule 425 under the Securities Act

___

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

___

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

___

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act






ITEM 1.02

TERMINATION OF A MATERIAL DEFINITIVE AGREEMENTS



Effective June 1, 2017 the previously announced Memorandum of Understanding (“MOU”) between Vitro Diagnostics, Inc. (the “Company”) and Caribbean GC Development Fund, Ltd., a Grand Cayman corporation (“Caribbean GC”) has been terminated without consummation.

The Company has no plans to further pursue the matter.




SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 

 

Vitro Diagnostics, Inc.
(Registrant)

 

 

 

 

Dated:

June 1, 2017

/s/ James R. Musick

 

 

James R. Musick, President and Chief Executive Officer




2